High dosage desferrioxamine therapy in a female patient with acquired aplastic anaemia and transfusion siderosis.
A 32 year old woman with severe aplastic anaemia required frequent transfusions and consequently developed hyperferrioxaemia (54 microMol/l) and hyperferritinaemia (1,700 ng/ml). For the treatment of transfusion siderosis she was given 18 high dose courses each comprising 35 g of desferrioxamine. Because of pre-existing thrombocytopenia (platelet count 5 X 10(9)/l) the iron chelating agent was given by continuous intravenous infusion over 3 1/2 days. High dose desferrioxamine had to be abandoned because of severe bone pain. The desferrioxamine infusions achieved a negative iron balance, iron loss after each infusion being 100 to 200 mg in the urine and 400 mg in the faeces. Serum iron and ferritin concentrations fell almost to normal. This report shows that faecal iron excretion must be taken into account in assessing the balance of iron input and output during desferrioxamine treatment.
D000328:Adult; D000741:Anemia, Aplastic / Q000473:pathology / Q000628:therapy*; D001853:Bone Marrow / Q000473:pathology; D003676:Deferoxamine / Q000008:administration & dosage* / Q000009:adverse effects; D005243:Feces / Q000378:metabolism; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007501:Iron / Q000378:metabolism; D012806:Siderosis / Q000188:drug therapy* / Q000378:metabolism
D005293:Ferritins; D007501:Iron; D003676:Deferoxamine